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Abstract 
Cholesterol is an essential substance involved in many functions, such as maintaining cell 
membranes, manufacturing vitamin D on surface of the skin, producing hormones, and pos-
sibly helping cell connections in the brain. When cholesterol levels rise in the blood, they 
can, however, have dangerous consequences. In particular, cholesterol has generated con-
siderable notoriety for its causative role in atherosclerosis, the leading cause of death in 
developed countries around the world. Homeostasis of cholesterol is centered on the me-
tabolism of lipoproteins, which mediate transport of the lipid to and from tissues. As a 
synopsis of the major events and proteins that manage lipoprotein homeostasis, this review 
contributes to the substantial attention that has recently been directed to this area. Despite 
intense scrutiny, the majority of phenotypic variation in total cholesterol and related traits 
eludes explanation by current genetic knowledge. This is somewhat disappointing consider-
ing heritability estimates have established these traits as highly genetic. Thus, the continued 
search for candidate genes, mutations, and mechanisms is vital to our understanding of heart 
disease at the molecular level. Furthermore, as marker development continues to predict 
risk of vascular illness, this knowledge has the potential to revolutionize treatment of this 
leading human disease. 
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Introduction 
The clinical manifestation of cholesterol buildup 
in arteries servicing the heart muscle causes more 
death and disability than all types of cancer combined 
(1). This is a remarkable outcome for a common, 
polycyclic lipid with the humble primary function of 
maintaining the permeability and fluidity of cell 
membranes. Nonetheless, cholesterol is required by 
all eukaryotic cells, which have specialized methods 
of recruiting and synthesizing the lipid only when it is 
needed. While effectively maintaining intracellular 
cholesterol homeostasis, these processes leave excess 
circulating though the body, leading to atherosclerotic 
plaque development and subsequent coronary artery 
disease. Thus, levels of cholesterol and related lipids 
circulating in plasma are important predictive tools 
utilized clinically to gauge risk of a cardiac event. For 
example, a rise in total cholesterol in men from 200 to 
240 mg DL-1 is associated with a three-fold increase in 
death from cardiac disease (2). 
While in circulation, cholesterol, being a lipid, 
requires a transport vesicle to shield it from the 
aqueous nature of plasma. Complex, micelle-like 
amalgamations of various proteins and lipids achieve 
cholesterol transport through the vascular system. 
These particles, intuitively known as lipoproteins, are 
heterogeneous in size, shape, composition, function, 
and perhaps most importantly, their contribution to 
vascular disease. High density lipoprotein (HDL) 
particles promote vascular health by extracting cho-
lesterol from tissues (including atherosclerotic 
plaques) and delivering it back to the liver. Con-
versely, low-density lipoproteins (LDLs) are the clas-Int. J. Biol. Sci. 2009, 5 
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sic antagonists of the circulatory system due to their 
propensity to bind to connective tissue in the intimal 
sub-layer of arteries (3). These processes are the mo-
tivation for the “good cholesterol,” and “bad choles-
terol” stigmas attached to HDL and LDL, respectively. 
Before any cholesterol reaches a particle of the HDL or 
LDL sub-fraction, it will usually have undergone a 
maturation process beginning with the hepatic or in-
testinal synthesis of very low density lipoprotein 
(VLDL). VLDLs, LDLs, and HDLs make up three of 
the six major sub-fractions of lipoproteins, which also 
include chylomicrons, chylomicron remnants (CRs), 
and intermediate density lipoproteins (IDLs). To-
gether, lipoprotein particles are heterogenous com-
posites of the stored forms of fatty acids and choles-
terol (triglycerides and cholesteryl esters, respec-
tively), amphipathic phospholipids, and apolipopro-
teins. 
High Density Lipoproteins and Reverse Cho-
lesterol Transport 
Particles of HDL prevent coronary artery disease 
by serving as transport particles for excess cholesterol 
to the liver, where it is converted into bile acids and 
excreted (Figure 1). In humans, HDL levels are a very 
well known measurement of cardiac health due to 
their strong inverse relationship with coronary artery 
disease (2, 4). The principal HDL pathway, termed 
reverse cholesterol transport (RCT) is a major com-
ponent of lipid homeostasis. Genetic variation among 
the RCT pathway contributes greatly to phenotypic 
variation in humans. Estimates using twin family 
studies have determined that nearly 50% of HDL 
phenotypic variability is genetic (5). These figures are 
controversial however, as it is possible that common 
mutations might contribute minor effects to lipid 
phenotypes (6). 
 
 
Figure 1. Reverse cholesterol transport pathway. Arrows are indicative of cholesterol movement and particle maturation. 
Cholesterol molecules are labeled “C”, and cholesterol esters “CE”.  Int. J. Biol. Sci. 2009, 5 
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Structural components of HDL 
The principal protein components of HDL are 
dual apolipoprotein (Apo) A1 peptides, which wrap 
around the particle in an anti-parallel, double-belt 
structure (7). Secondary structure of ApoA1 consists 
of ten transmembrane amphipathic α-helices (8). 
Functionally, ApoA1 forms the initial structure of 
discoidal HDL (9), and is recognized by some of the 
most important proteins involved in RCT including: 
lecithin-cholesterol acyltransferase (LCAT) (10), ATP 
binding cassette A1 (ABCA1) (11), and the scavenger 
receptor BI (SR-BI) (12). Therefore, ApoA1 is not only 
the primary structural component; it serves as the 
recognition molecule for most of the proteins that 
interact with HDL. ApoA1-deficient mice do not form 
normal HDL particles and exhibit 70-80% reductions 
in both plasma cholesterol and HDL (13). Human 
studies have concluded that mutations in ApoA1 ex-
hibit the most profound effects on accelerated 
atherosclerosis compared to other RCT proteins (14). 
However, some ApoA1 mutations reduce levels of 
circulating HDL, but are reported to actually decrease 
risk of cardiac events. Notably, the ApoA1  milano 
(R173C) mutation has been implicated in improved 
circulatory health despite leading to reduced HDL 
and hypertriglyceridemia (15).  Franceschini et al. 
provided a possible explanation for this anomaly 
when they concluded that mice carrying the ApoA1 
milano mutation had more efficient cholesterol efflux 
capabilities then their wild-type littermates (16). This 
finding has recently been challenged, as Weibel and 
colleague’s 2007 study compared efflux potentials of 
ApoA1 wild-type and milano rats from 3 different cell 
types, and determined that efflux rates were not sig-
nificantly different (17). Certainly, the elusive details 
of the potential atheroprotective effects resulting from 
ApoA1 mutations such as milano are worthy of intense 
scrutiny. 
Cholesterol efflux into nascent HDL 
The rate-limiting step in RCT is cholesterol ef-
flux, a process mediated largely by the ABCA1 gene 
product. ABCA1 promotes cholesterol efflux by cata-
lyzing the transfer of cholesterol and phospholipids 
from potentially atherogenic cells in peripheral tissues 
to discoidal HDL (11) (Figure 1). ABCA1 induced 
cholesterol efflux is especially combatant to vascular 
disease when cholesterol is taken from macrophages 
inside artery walls because their cholesterol-induced 
differentiation into foam cells is the foundation of 
atherogenesis (18). The efflux process initiates as dis-
coidal HDL binds to ABCA1 o n  t h e  c e l l  s u r f a c e ,  i s  
internalized, and then transported into endocytic 
vesicles inside the cell (19). While inside endosomes, 
ABCA1 and the Niemann-Pick C1 protein mediate the 
transfer of lipid pools into intracellular HDL (20). The 
complex then returns to the cell surface and dissoci-
ates, thus releasing the cholesterol-enriched 
pre-β2-HDL undegraded (19).   
Genetic studies have definitively established the 
crucial involvement of ABCA1 with HDL genesis. 
Humans with ABCA1 inactivating mutations have 
Tangier disease, which is marked by orange, choles-
terol ester laden tonsils, peripheral neuropathy, and 
strong predisposition to coronary artery disease 
caused by the virtual absence of HDL (18, 21). Several 
recent studies have identified more common muta-
tions that play important roles in HDL homeostasis. 
For example, in their study of patients with the low 
HDL levels, Cohen et al. identified an ABCA1 muta-
tion in 20 of 128 individuals (22). Furthermore, 
large-population studies have estimated that ABCA1 
mutations are responsible for 10% of low HDL cases 
in the general population (22, 23). 
HDL maturation 
During HDL maturation, discoidal pre-β-HDL is 
converted into spherical α-HDL via LCAT mediated 
conversion of cholesterol into cholesteryl esters (Fig-
ure 1). The 416 amino acid LCAT protein is synthe-
sized in the liver and secreted into circulation (24), 
where it exists both bound to lipoproteins and 
lipid-free (25). On HDL particles, LCAT generates 
cholesterol esters by catalyzing the transfer of the 
2-acyl group of lecithin to the hydroxyl group of cho-
lesterol (26) (Figure 2). LCAT also can esterify choles-
terol in LDL, but HDL is the preferred lipoprotein 
substrate due to the presence of ApoA1, which is a 
cofactor (27). Cholesterol esters are more hydrophobic 
than free cholesterol, and accumulate in the center of 
HDL particles causing a change in the geometry from 
discoidal to spherical (Figure 1). This process is crucial 
to cholesterol efflux because it helps maintain a con-
centration gradient favoring addition of free choles-
terol to lipoproteins including HDL (28, 29). 
In humans, LCAT inactivating mutations cause 
familial LCAT deficiency (FLD), which is character-
ized by severe corneal opacification, low plasma 
HDL, sharply increased LDL triglycerides, and ac-
cumulation of discoidal HDL in plasma (30). Addi-
tionally, some LCAT defects disrupt interaction with 
ApoA1, which leads to fish eye disease, decreased 
HDL (but not LDL), decreased cholesterol esters, and 
similar but milder phenotypes compared to FLD (30, 
31). Int. J. Biol. Sci. 2009, 5 
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Figure 2. Representation of the molecular activity of the LCAT protein. 
 
Lipase activity 
In order to understand HDL metabolism, it is 
important to be aware that lipoproteins of each class 
are heterogeneous particles that heavily interact with, 
and often change into one another. A common factor 
influencing lipoprotein interaction is activity of lipase 
proteins. Lipases are water-soluble enzymes that hy-
drolyze ester bonds of water-insoluble substrates such 
as triglycerides, phospholipids, and cholesteryl esters 
(32). Endothelial lipase (LIPG), hepatic lipase (LIPC), 
and lipoprotein lipase (LPL) are three vascular lipase 
proteins that migrate to endothelial cells and anchor 
to the distal side via interaction with heparin sulfate 
proteoglycans (33-35). The exposed lipase proteins 
remodel circulating lipoproteins, generating impor-
tant effects to lipoprotein metabolism and cholesterol 
homeostasis. Additionally, some lipase enzymes di-
rectly interact with lipoprotein receptors, such as the 
LDL receptor, enhancing metabolism of circulating 
lipoproteins. 
The majority of the catalytic activity of LIPG is 
devoted to hydrolysis of phospholipids of VLDL, 
chylomicrons, and HDL (33). Interestingly, LIPG me-
diated phospholipid modulation of HDL inhibits 
cholesterol efflux from SR-BI, but enhances efflux 
from ABCA1, and HDL uptake in the liver (36). In 
2006, Badellino and colleagues (37) established a cor-
relation between LIPG and atherosclerosis, which 
underscores the importance of SR-BI cholesterol efflux 
and HDL longevity in ideal HDL function.   
The LIPC protein is synthesized primarily by 
hepatocytes, and then secreted and bound to the ex-
tracellular matrix of hepatic endothelial cells (38). 
LIPC has powerful VLDL and IDL triglyceride hy-
drolysis capabilities (39), as well as the ability to 
catalyze conversion of α-HDL subspecies HDL2 to 
denser HDL3 (40) (Figure 1). The latter functionality 
has direct implications to RCT because HDL2 is more 
likely to interact with SR-BI for cholesterol efflux or 
endocytosis (41). Independently of RCT, LIPC appears 
to demonstrate pro-atherogenic effects by increasing 
artery wall retention of VLDL, chylomicrons, and 
LDL (42). Although mutations in human LIPC are 
associated with variations in HDL concentration, the 
connection with coronary artery disease is controver-
sial (43, 44). 
LPL is a critical enzyme involved in hydrolysis 
of triglyceride rich lipoprotein particles in muscle, 
adipose, and macrophages, a process which generates 
free fatty acids and glycerol for energy metabolism 
and storage (45). Expression of LPL has been impli-
cated in atherosclerosis, citing the increased affinity 
for macrophage phagocytosis (and subsequent foam 
cell development) on LDL and chylomicron particles 
after LPL mediated remodeling (46). 
Lipoprotein remodeling in circulation 
Cholesterol homeostasis is greatly modulated by 
proteins that catalyze the exchange of cholesterol and 
other lipids between circulating lipoprotein classes. 
Mutations in lipid transfer proteins are very impor-
tant sources of lipoprotein phenotypic variation, as 
the genes are decidedly polymorphic. In plasma, there Int. J. Biol. Sci. 2009, 5 
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are two important lipid transfer proteins: cholesteryl 
ester transfer protein (CETP), and phospholipid 
transfer protein (PLTP). 
CETP catalyzes the exchange of cholesteryl es-
ters inside HDL for triglycerides of LDL and VLDL 
(Figure 1) (47). Expression of CETP is fairly ubiqui-
tous, however most is synthesized in the liver, and 
then excreted and bound to HDL in circulation (48). 
Theoretically, CETP activity is attributed to coronary 
artery disease, as the movement of cholesterol from 
HDL to LDL is certainly pro-atherogenic. Surpris-
ingly, studies have failed to clearly identify the rela-
tionship between CETP and atherosclerosis, suggest-
ing additional function of the protein. In mice (which 
naturally lack CETP), expression of the human 
ortholog has been found to be both pro-atherogenic 
(49), and anti-atherogenic (50), depending on the 
metabolic state of the mouse model. In humans, 
markedly increased HDL has been a consistent find-
ing in carriers of CETP nullifying mutations (51, 52). 
Some carriers of inactivated CETP have been linked to 
increased longevity (51), while other studies have 
reported no association (53), and still other mutations 
implicate increased risk of coronary artery disease 
(54). The CETP gene, located on human chromosome 
16q21 is highly polymorphic. One important poly-
morphism, Taq1B, accounted for 5.8% of of the varia-
tion in HDL in a Spanish population (55), and appears 
associated with coronary artery disease (56).  
PLTP regulates the size and composition of HDL 
both by lipid exchange and particle remodeling. The 
gene is located on human chromosome 20q12-q13.1, 
and is expressed primary (but not solely) by adipo-
cytes and hepatocytes (57). In circulation, normal 
PLTP activity appears protective against atheroscle-
rosis due to its ability to both increase circulating lev-
els of cholesterol efflux prone pre-β-HDL and to 
maintain levels of mature HDL. PLTP is able to cata-
lyze the fusion of two HDL3 particles, forming one 
larger HDL2, while releasing lipid poor ApoA1, the 
precursor to pre-β-HDL (58). Enrichment of HDL with 
triglycerides enhances this process (59), otherwise 
known as HDL conversion. In addition to HDL con-
version, PLTP facilitates the transfer of phospholipids 
and to a lesser extent, cholesterol from triglyceride 
rich lipoproteins such as VLDL and chylomicrons into 
HDL (60, 61). PLTP inactivated mice have 60-70% 
lower HDL (62), which suggests that phospholipid 
migration into HDL impedes catabolism of the parti-
cle. Transgenic mice overexpressing PLTP have se-
verely reduced HDL and inhibited RCT, despite in-
creased levels of pre-β-HDL (63, 64). This activity has 
been linked to increased HDL catabolism (63), and 
excessive HDL conversion, a conclusion that chal-
lenges the theory that pre-β-HDL particles are more 
important for cholesterol efflux then α-HDL (64). 
While these studies in animal models generate as 
many questions as answers, together they indicate 
that correctly balanced PLTP activity is essential in 
maintaining normal plasma HDL concentration. 
The duality of the scavenger receptor class B 
type I protein 
Ultimately, the protective effects generated by 
RCT are accomplished through the removal of excess 
cholesterol (cholesterol efflux), and delivery of cho-
lesterol rich lipoprotein particles to liver hepatocytes 
for lipid excretion (HDL clearance). The SR-BI protein 
is very unique because it plays an integral role in both 
of these processes. The gene is expressed primarily in 
adrenal tissues and the liver, where it is attached to 
epithelial surfaces (65). Studies in humans and animal 
models have established SR-BI as vital to cholesterol 
homeostasis. Mice with inactivated SR-BI have a 
twofold increase in plasma cholesterol, which is dis-
tributed in unusually large and homogenous HDL 
particles (66). Furthermore, a separate study linked 
greatly reduced clearance of HDL from plasma to 
SR-BI deficiency (67). These observations strongly 
suggest that SR-BI is required to maintain normal 
cholesterol.  
SR-BI is most notorious for catalyzing uptake of 
cholesterol from lipid-rich HDL particles into hepa-
tocytes, where it is converted into bile acids. The 
mechanism of HDL clearance is distinct from ABCA1 
mediated cholesterol efflux and low density lipopro-
tein receptor endocytosis in that internalization of the 
entire particle does not occur, but rather cholesteryl 
esters are selectively taken into tissues (68). In this 
way, mature α-HDL can quickly be recycled back into 
lipid-poor pre-β-HDL, and RCT can start again. Af-
finity of lipoprotein/SR-BI interaction is complex and 
highly related to apolipoprotein composition and 
particle geometry. SR-BI binds both LDL and HDL; 
however, preference is strongest for lipoproteins 
containing ApoA1, which it binds to tightly (69). In 
fact, three HDL associated apolipoproteins, ApoA1, 
ApoA2, and ApoC3, each interact with SR-BI, and 
increase affinity for cholesterol movement (70). 
The availability of LDLR to commit lipoprotein 
endocytosis is regulated by Proprotein Convertase 
Subtilisin Kexin type 9 (PCSK9). In fact, this relation-
ship is important enough to instigate a distinct classi-
fication of familial hypercholesterolemia (known as 
FH3), which is caused by mutations in PCSK9 (71). 
Secreted PCSK9 competes with lipoprotein-associated 
apolipoproteins as a ligand for LDLR by binding to 
the receptor and causing endocytosis and degradation Int. J. Biol. Sci. 2009, 5 
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of the complex (72). Additionally, PCSK9 appears to 
interrupt intracellular receptor recycling by binding to 
LDLR prior to its placement on the surface of hepa-
tocytes (73). The molecular processes involved in 
PCSK9 induced degradation are not clear, although 
Geoghegan et al. have elucidated that PCSK9 exhibits 
acylenzyme activity on LDLR, in which residue 
Gln152 of the receptor is esterified by Ser386 of PCSK9 
(74). This study, and independent genetic studies 
have shown that the EGFP domain of LDLR is the 
active site of PCSK9 interaction (75). The FH3 pheno-
type is rare, and is derived from missense mutations 
that increase functionality of PCSK9. However, this 
effect is not the only clinically important mutation in 
PCSK9, as loss-of-function mutations appear to gen-
erate positive effects on blood lipids. The 2005 Dallas 
Heart study identified two PCSK9 nonsense muta-
tions among subjects with low plasma LDL levels: 
Y142X in exon 3, and C679X in exon 12 (76). These 
mutations led to 28% decreased LDL levels, and sig-
nificant reductions in risk of coronary artery disease. 
PCSK9 induced hypocholesterolemia has also been 
identified in Japanese (77), and Italian (78) patients. 
As previously mentioned, SR-BI plays a key role 
in cholesterol efflux by acting as a cholesterol donor to 
HDL. Unlike ABCA1 mediated cholesterol efflux, 
which targets pre-β-HDL, the ideal lipoprotein for 
SR-BI mediated efflux is large, phospholipid-rich, 
spherical HDL2 (79, 41). Thus, SR-BI is a bidirectional 
cholesterol transporter to and from mature HDL, and 
is one of the most important proteins to RCT.  
Hepatic bile acid synthesis 
Cholesterol delivered to the liver via HDL enters 
the bile acid synthesis pathway (also known as the 
cholesterol catabolic pathway), which begins with the 
enzymatic modulation of hepatic cholesterol to 
7-α-hydroxycholesterol by cholesterol 
7-α-hydroxylase (CYP7A1) (80). Transcriptional ac-
tivity of CYP7A1 dictates the efficacy of the choles-
terol catabolic pathway, and is critical to hepatic cho-
lesterol homeostasis. One of many important tran-
scriptional regulators of CYP7A1 is the Farnesoid X 
receptor (FXR). FXR acts as a bile acid sensor, sup-
pressing CYP7A1 activity when hepatic concentra-
tions of bile salts are high (81). FXR does not work on 
its target directly, but instead upon activation, it trig-
gers a cascade involving small heterodimer partner 1 
(SHP-1), which activates the direct CYPA1 inhibitor, 
liver receptor homolog 1 (LRH-1) (82). Not surpris-
ingly, homozygous deletion of CYPA1 results in in-
creased hepatic cholesterol content, deficient bile acid 
secretion, and hypertriglyceridemia (83). The re-
maining steps in the conversion of cholesterol into 
conjugated bile salts such as taurocholic and gly-
cocholic acid involve at least 16 enzymes. After syn-
thesis, these bile acids cycle from the liver, to the gall 
bladder, into the duodenum sub-layer of the intestine, 
back through enterocytes of the ileum, through the 
portal vein, and back into hepatocytes several times 
per day while carrying out their primary function of 
aiding lipid digestion (84). 
Low Density Lipoproteins and Cholesterol 
Distribution  
The mechanisms that manage and utilize LDL 
are tightly controlled systems evolved to distribute 
cholesterol through the circulatory system and into 
cells that require extracellular cholesterol. Unfortu-
nately, LDL-cholesterol does not always reach its 
most appropriate destination, but rather accumulates 
in artery walls causing atherosclerosis, the leading 
cause of death and disability in the developed world 
(85). For this reason, the quantity of circulating LDL is 
a well-known risk factor for heart disease, and is the 
primary focus of most lipid lowering therapies (86). 
The pathogenicity of LDL and likelihood of athero-
sclerotic development are heavily influenced by ge-
netic composition of gene products involved with 
LDL metabolism. Patients with genetic defects that 
cause severely elevated LDL have familial hypercho-
lesterolemia, which affects approximately 1:500 peo-
ple (87), and is the consequence of mutations in the 
low density lipoprotein receptor (LDLR), ApoB, and other 
genes. In normal individuals, approximately 50% of 
LDL variation is genetic. This section will address the 
mechanisms behind exogenous and endogenous cho-
lesterol transport, with emphasis placed on the pro-
teins that participate in this crucial pathway. 
Exogenous lipid metabolism in the intestine 
The amount of cholesterol absorbed from the 
diet is a major contributor to levels of cholesterol in 
circulation. One study has estimated that the complete 
abolition of dietary cholesterol absorption would re-
duce plasma cholesterol by up to 62% (88). About 50% 
of dietary cholesterol is absorbed through intestinal 
enterocytes, while the rest is excreted through feces 
(89). This figure however, is extremely variable 
among individuals and this variation has been estab-
lished as an inherited trait (90). Thus, the mechanisms 
behind the entry of dietary cholesterol into the body 
are critical sources of variation in cholesterol homeo-
stasis. 
Early lipid digestion, from the oral cavity to the 
duodenum sub-layer of the intestine, produce crude 
emulsions consisting of free cholesterol, triglycerides, 
free fatty acids, and phospholipids. As these emul-Int. J. Biol. Sci. 2009, 5 
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sions are delivered into the intestine, they are mixed 
with bile salt micelles, which are synthesized and se-
creted into the intestine from the liver (91). Total 
concentration of bile salt micelles is positively corre-
lated with cholesterol absorption (92), due to catalysis 
of lipid emulsification into smaller droplets, which 
interact more readily with lipase enzymes (93). Bile 
salt emulsified triglycerides and cholesteryl esters are 
hydrolyzed by pancreatic lipase (PL) (94), and car-
boxyl ester lipase (CEL) (95), respectively. Not sur-
prisingly, in vivo knockout studies using murine 
models have confirmed the necessity of both PL (93) 
and CEL (95) to normal cholesterol absorption, and 
chylomicron assembly.   
Cholesterol absorption is achieved through pas-
sage across brush border membranes and into intes-
tinal enterocytes in the jejunum. While details of the 
mechanism are still unclear, recent studies have iden-
tified key proteins. One major breakthrough came 
with the identification of the substrate for the drug 
ezetimibe (brand: Zetia), which inhibits cholesterol 
entry into enterocytes without effecting de novo cho-
lesterol biosynthesis (96). Ezetimibe was approved by 
the United States Food and Drug Administration for 
treatment of hyperlipidemia in 2002, however, it took 
two additional years before Garcia-Calvo and col-
leagues discovered that the Niemann-Pick C1-Like 1 
(NPC1L1) protein is the target of the drug (97). 
NPC1L1 is a putative transporter of cholesterol, and is 
expressed on the brush border membranes of entero-
cytes in a general pattern that parallels that of maxi-
mum cholesterol absorption (98). Naturally occurring 
mutations in human NPC1L1 are associated with re-
duced cholesterol absorption and circulating levels of 
LDL (99). In addition to NPC1L1, the ATP binding 
cassette G5 and G8 proteins (ABCG5/8) appear to 
negatively regulate cholesterol transport into entero-
cytes. Mutations in the ABCG5/G8 genes (they are 
neighbors on human chromosome 2p21) are associ-
ated with sitosterolemia, which is characterized by 
increased absorption of plant sterols. Interestingly, 
sitosterolemic patients also have increased amounts of 
dietary cholesterol absorption and premature athero-
sclerosis (100). This data has been interpreted as evi-
dence that ABCG5/G8 form a complex that promotes 
secretion of cholesterol back into the intestinal lumen, 
and that this activity targets plant sterols in normal 
individuals (101). 
Movement of exogenous cholesterol from the 
intestines to the liver 
Once inside enterocytes, dietary cholesterol is 
packaged into chylomicrons, and put into circulation. 
This process is initiated by the esterification of large 
amounts of free cholesterol by the cholesteryl trans-
ferase protein (102), and the synthesis of triglycerides 
from free fatty acids by mono- and di-acylglycerol 
acyltransferases (101). In the endoplasmic reticulum, 
cholesteryl esters, phospholipids and triglycerides are 
amalgamated together with ApoB-48 by the micro-
somal triglyceride transfer protein (MTP) (103). The 
action of MTP is not localized to enterocytes, or even 
to chylomicron synthesis, instead it is nearly ubiqui-
tously expressed and a crucial element of VLDL syn-
thesis as well. Inactivating mutations in MTP result in 
abetalipoproteinemia, in which chylomicrons and 
VLDL are not synthesized, ApoB containing particles 
in general are absent, and lipids accumulate in the 
intestine (104). As nascent chylomicron synthesis 
nears completion, the particles are transported to the 
Golgi apparatus where additional triglycerides are 
recruited, and then the particles are transported via 
vesicular structures to clatherin-coated pits and exo-
cytosed (105).   
ApoB is the major protein component of all lipo-
proteins except HDL. During chylomicron synthesis 
in the intestine, ApoB mRNA sequence is altered by 
the apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide 1 (APOBEC1) protein, so that the 6666th 
nucleotide is changed from a cytosine to a uracil (106). 
This unique process leads to a premature UAA stop 
codon, and production of a truncated ApoB peptide 
only 48% the length of full ApoB (106). APOBEC1 
inactivated mice demonstrate a complete lack of 
ApoB-48, 178% more ApoB-100, and decreased HDL 
cholesterol (107). Mutations in the ApoB gene itself are 
an important source of phenotypic variation in hu-
mans. In a recent review, 132 genetic variants in the 
ApoB gene are listed including one in the promoter 
region, one in the 5’ untranslated region, 85 in the 
coding region (22 synonymous), 44 in the various in-
trons, and one in the 3’ UTR (108). Notably, genotypes 
of the very common T2488T and E4154K mutations 
have crucial implications to LDL homeostasis (109, 
110). Considering that ApoB is a direct measurement 
of potentially atherogenic particles, the levels of ApoB 
levels in circulation are considered a more appropri-
ate trait to measure risk of cardiovascular disease than 
LDL (111), however, LDL levels remain more clini-
cally utilized. 
While the digestion and packaging of dietary 
lipids into chylomicrons takes about one hour, the 
halflife of lipids in chylomicrons is only 4.5 minutes 
(112). Upon exiting enterocytes, the only protein 
component of chylomicrons is ApoB-48. After passage 
through the throacic duct and into the bloodstream, 
nascent chylomicrons accept ApoC2 and ApoE from 
HDL, a process that yields mature chylomicrons. As Int. J. Biol. Sci. 2009, 5 
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mature chylomicrons circulate, the newly acquired 
ApoC2 on the particle surface activates LPL, which is 
bound to epithelial surfaces of capillaries in adipose 
and muscle tissue where it is differentially expressed 
according to fed/fasting conditions (45). LPL cata-
lyzes the hydrolysis of triglycerides in chylomicrons, 
a crucial process that distributes fatty acids to tissues, 
generates non-esterified fatty acids in plasma, and 
remodels chylomicrons into CRs (45). The absence of 
LPL causes familial LPL deficiency, which is charac-
terized by hypertriglyceridemia, decreased HDL and 
LDL, and massive accumulation of chylomicrons in 
plasma (113). As chylomicrons shed triglycerides to 
epithelial cells, ApoC2 is lost (ApoE is retained), and 
as a result, the CR loses further lipase activation. 
As CRs lose triglycerides, they become enriched 
in ApoE, and consequently are destined for the liver. 
ApoE peptides are essential for particle uptake into 
hepatocytes, as demonstrated by ApoE inactivated 
mice, which demonstrate negligible CR clearance 
(114). The model for hepatic clearance involves ApoE 
interaction with hepatocyte cell surface molecules 
including heparin sulfate proteoglycans and LIPC, 
followed by an endocytosis step mediated by a com-
plex of LDLR and the low density lipoprotein related 
1 protein (LRP1) (115). Another factor influencing CR 
uptake is cholesterol content of the macromolecule. 
Chylomicron-like particles, created without choles-
terol, undergo triglyceride hydrolysis by LPL but are 
not taken up by hepatocytes (116). This result has 
been interpreted as a failure of ApoE to attain the 
necessary conformation to achieve receptor binding 
with LRP1 (116). After delivery to the liver, CR lipids 
are hydrolyzed once again into free fatty acids and 
free cholesterol for eventual synthesis of VLDL. 
VLDL synthesis and maturation into LDL 
The assembly of VLDL begins inside the rough 
endoplasmic reticulum of hepatocytes, at the site of 
ApoB-100 translation. As the peptide is synthesized by 
membrane bound ribosomes, it is sent through a pro-
tein channel into the cytoplasm. Meanwhile, the 
aforementioned MTP binds the precursor peptide and 
recruits a small amount of triglycerides, phospholip-
ids, and cholesteryl esters, allowing ApoB-100 to fold 
around a small lipid core (117). Next, the bulk of 
VLDL triglycerides are transferred into the precursor 
particle, and the now larger precursor (sometimes 
referred to as VLDL2) is sorted to the Golgi apparatus. 
Evidence for a two-step maturation system up to this 
point is given by experiments using Brefeldin A 
(BFA), which inhibits only the transition into VLDL2, 
and not the initial lipidation of ApoB-100 (118). BFA 
selectively inhibits the ADP-ribosylation factor (ARF) 
protein, suggesting that ARF is a critical factor in 
VLDL assembly (118). Once in the Golgi, additional 
lipids are recruited to form the mature VLDL particle, 
but the mechanism behind thi s  b e h a v i o r  i s  n o t  y e t  
clear. However, it is certain that the fatty acids used 
for the synthesis of VLDL are derived from triglyc-
erides stored in cytosolic lipid droplets (119), so it is 
likely that the concentration of these lipids is the rate 
limiting property of VLDL biogenesis. 
Just like chylomicrons, VLDLs exchange ApoC2 
and ApoE with HDL in circulation, and distribute free 
fatty acids to muscle and adipose tissues expressing 
LPL. As remodeled VLDL particles lose triglycerides 
and ApoC2, they become IDLs, which are either re-
moved by the liver or are subject to further lipase ac-
tivity and develop into LDL. Endocytosis of IDL by 
the liver includes not only LDLR, but also other re-
ceptors in the same class including the very low den-
sity lipoprotein receptor (120), and LRP1 (115). Larger, 
triglyceride-rich IDL particles are generally more 
susceptible to liver re-uptake by these receptors 
compared to smaller particles, which are more likely 
to transition into LDL (121). The triglyceride content 
(and subsequently, the size and metabolic fate) of IDL 
particles is heavily influenced by LIPC (39), as well as 
CETP, (47) and PLTP (60). LDL particles have a rela-
tively long half-life of about 3 days (122), a property 
attributed to the lack of receptor and lipase activating 
apolipoproteins, as well as the stability of cholesteryl 
esters inside the macromolecules. 
Variation among VLDL, IDL, LDL, and HDL 
levels in circulation are highly dependent on the ge-
netic composition of ApoE. Mice lacking functional 
ApoE have 500% more plasma cholesterol, and rapidly 
develop severe atherosclerosis compared to wild type 
mice (114). This effect is presumably from a complete 
loss of LDLR binding and chylomicron/LDL clear-
ance (123). Due to their tendency to develop athero-
sclerotic plaques, the ApoE knockout mouse model is 
a very commonly used model for human atheroscle-
rosis. In humans, ApoE contains two very common 
SNPs at amino acid positions 112 and 158, which dic-
tate the ApoE2, E3, and E4 genotype nomenclature 
(124). The ApoE4 appears to be associated with de-
creased HDL, increased LDL, and increased plasma 
cholesterol, while the E2 genotype has the opposite 
effect (125, 126). 
Intracellular cholesterol metabolism 
LDLR is responsible for uptake of cholesterol 
carrying lipoproteins. The principal ligand for the 
receptor is ApoB-100 on LDL, however LDLR can 
catalyze endocytosis of lipoproteins containing mul-
tiple copies of ApoE such as VLDL, IDL, and HDL. Int. J. Biol. Sci. 2009, 5 
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The extracellular portion of L D L R  c o n s i s t s  o f  t h r e e  
protein modules including a domain with seven con-
tiguous cysteine-rich repeats (referred to as LDLR 
type A, or LA domains), a 400-amino acid sequence 
that is strongly homologous to the epidermal growth 
factor precursor protein (referred to as the EGFP do-
main), and a 58-residue sequence rich in serine and 
threonine (Figure 4) (127). Genetic studies have re-
vealed that LA domains 3-7 are required for effective 
binding of LDL, while only LA5 is required for VLDL 
uptake (128). Studies utilizing antibody blocking and 
synthetic peptides have determined that amino acid 
residues ~3300-3600 of ApoB-100 are the active sites 
for LDL interaction with LDLR (129, 130). 
Figure 4 describes the intracellular process in 
LDL endocytosis. LDLR positioning and subsequent 
endocytosis of the receptor-ligand complex occurs at 
clathrin coated pits (131). After endocytosis, acidic 
conditions of the endosome catalyze disassociation of 
LDL from the LDLR. Genetic studies have implicated 
the EGFP domain of LDLR as responsible for release 
of LDL, as deletion of this region produces a 
non-separable complex (132). After release of the 
lipoprotein, the LDLR peptide is recycled back to the 
membrane in a process also controlled by the EGFP 
domain (132). Meanwhile, LDL particles that are re-
leased from the receptor fuse into lysosomes, and are 
degraded into lipid components and amino acids by 
enzymes of the vesicle. Large portions of lipids re-
leased are cholesteryl esters, which are hydrolyzed by 
lysosomal acid lipase (LIPA) into free cholesterol. 
Patients with complete and heterozygous LIPA defi-
ciency have Wolman disease and cholesteryl ester 
storage disease, respectively (133). The consequences 
of inactive LIPA are severe: liver failure, hypercho-
lesterolemia, hypertriglyceridaemia, liver fibrosis, 
early atherosclerosis, and early death (133). Choles-
terol that has been endocytosed and converted to free 
form is often incorporated into cell membranes, 
however depending on cell type, it has several other 
possible fates including efflux to cellular adaptors, 
conversion back into cholesterol esters, metabolism 
into bile acids, or synthesis of steroids (134). Regard-
less of metabolic fate, levels of intracellular cholesterol 
are the controlling element behind overall cholesterol 
homeostasis of every cell via their impact on regulat-
ing LDLR protein and de novo cholesterol synthesis.  
 
 
 
Figure 3. Transport of exogenous cholesterol, and de novo cholesterol requires a diversity of lipoproteins and proteins, as 
shown above. Int. J. Biol. Sci. 2009, 5 
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Figure 4: The LDLR structure contains three types of domain: LDLR-type A domains (LA), the epidermal growth factor 
precursor protein-like domain (EGPF), and a domain rich in serine and threonine residues. The endocytotic process is also 
shown, which yields free intracellular cholesterol [see (127) with permission]. 
 
End product feedback regulation of LDLR 
and HMG Co-A reductase 
In addition to endocytosis of lipoproteins, mam-
malian cells increase cholesterol levels through de 
novo synthesis beginning from acetyl-CoA. The rate 
limiting reaction of the cholesterol biosynthesis 
pathway is production of mevalonate by HMG-CoA 
reductase (135). Expression levels of HMG-CoA re-
ductase as well as LDLR are negatively controlled by 
intracellular cholesterol, which as a result, commands 
a powerful system of self-regulation.  
Transcription levels of both LDLR and HMG-CoA 
reductase genes are controlled by promoters with 
sterol regulatory elements (SREs), which are present 
on over 30 genes involved with lipid synthesis and 
uptake (136). Experiments using chimeric LDLR 
promoter and reporter gene constructs have localized 
the area of sterol responsiveness to 8bp of palin-
dromic sequence, (5'-CACCCCAC-3') (137). The SRE 
in the HMG-CoA reductase promoter is homologous to 
LDLR SRE, with a substitution of a guanine for the 
central cytosine on the 3’ side (138). In both promot-
ers, attachment of transcription factors called SRE 
binding proteins (SREBPs) is required for efficient 
production of downstream transcription. There are 
three types of SREBP, (SREBP1a, SREBP1c, and 
SREBP2), which are encoded by two genes. Of the 
three isoforms, SREBP1a and SREBP2 are more im-
portant in cholesterol homeostasis than SREBP1c, 
which mainly alters expression of fatty acid synthesis 
genes (139). Despite discrepancies in their transcrip-
tional targets, proteolytic activation of each SREBP 
isoform is regulated by cholesterol through a common 
mechanism. Complete disruption of SREBP activation 
in mice hepatocytes results in 75% decrease in sterol 
and fatty acid synthesis, 50% reduction in LDLR 
mRNA and LDL clearance, and a significant reduction 
in total plasma cholesterol (140). 
The molecular basis for cholesterol sensitivity of 
SREBP has been elucidated greatly due to the efforts 
made by the Brown and Goldstein Lab of the Univer-Int. J. Biol. Sci. 2009, 5 
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sity of Texas Southwestern Medical Center. Each 
newly translated SREBP is inserted into the ER mem-
brane, where its C-terminal regulatory domain binds 
to the C-terminal of the SREBP cleavage activating 
protein (SCAP) (139). While associated with SREBP, 
SCAP binds to another ER bound protein known as 
insulin induced gene 1 (INSIG) (141). Interaction be-
tween SCAP and INSIG keeps the protein complex 
firmly in place in the ER. Importantly, this interaction 
between SCAP and INSIG is cholesterol-sensitive, and 
thus, acts as the cholesterol sensor of this system (142). 
In cholesterol abundant conditions, mem-
brane-spanning domains of SCAP bind to cholesterol, 
causing a conformational change in the cytosolic do-
main between domains 7 and 8, resulting in strong 
affinity for INSIG (142). The cholesterol-absent con-
formation of SCAP is not associated with INSIG, 
leaving the SREBP/SCAP complex free to leave the 
ER in COPII vesicles, which then migrate to the Golgi 
(143). Once there, the N-terminal transcription factor 
domain of SREBP is cleaved in a two-step process 
involving proteolytic enzymes site-1 and site-2 pro-
teases (S1P and S2P, respectively) (144). The nuclear 
form of SREBP migrates into the nucleus and activates 
genes including HMG CoA reductase and LDLR, ulti-
mately leading to increased cholesterol concentration 
in the cell.  
Mutations in genes involved in the cholesterol 
biofeedback pathway produce powerful effects on 
cholesterol homeostasis, especially those in genes that 
encode cholesterol biosynthetic enzymes. Inactivating 
mutations in the cholesterol biosynthetic pathway 
cause accumulation of cholesterol precursors, which 
manifest other serious health defects besides dyslipi-
demia. A table of several monogenic diseases in this 
pathway is included (Table 1). 
Table 1. Monogenic disorders of the cholesterol biosyn-
thesis pathways and the loci that harbor the causative 
mutations. 
Disorder Locus  Ref.
HMG-CoA synthase defi-
ciency  
HMG-CoA synthase  (145)
Mevalonic aciduria   Mevalonate kinase  (146)
Hyperimmunoglobulinemia D 
syndrome 
Mevalonate kinase  (146)
Desmosterolosis 24-dehydrocholesterol  re-
ductase 
(147)
CHILD syndrome  NAD(P) dependent steroid 
dehydrogenase-like 
(148)
Conradi-Hunermann syn-
drome 
Emopamil binding protein  (149)
Lathosterolosis Sterol-C5-desaturase  (150)
Smith-Lemli-Opitz syndrome  7-dehydrocholesterol re-
ductase 
(151)
Summary 
Cells collect cholesterol molecules through de 
novo synthesis, or receptor mediated endocytosis of 
exogenous and endogenous cholesterol packaged in 
LDL. Extracellular cholesterol is initially packaged 
into triglyceride rich particles, which are hydrolyzed 
in circulation to move fatty acids into cells expressing 
LPL. As lipoproteins undergo triglyceride hydrolysis, 
they become increasingly dense and choles-
terol-laden. Cholesteryl ester-rich lipoproteins inter-
act with the LDLR, which is expressed selectively by 
the liver, and by cells low in intercellular cholesterol. 
Meanwhile, the liver is consistently manufacturing 
HDL particles, which have the critical task of remov-
ing excess cholesterol from LDL particles, and the 
minute spaces that they might accumulate. Together, 
these systems interact, sharing various proteins and 
lipids in order to maintain the balance of the famously 
deadly but undeniably vital cyclic lipid, cholesterol. 
The appeal of HDL lies in its ability to undo 
cholesterol accumulation in tissues. Conversely, LDL 
demands our attention so that we may comprehend 
the mechanisms that lead to heart disease. Unfortu-
nately, the extremely polygenic and complex mecha-
nisms that influence cholesterol homeostasis con-
found experimental design so that only narrow hy-
potheses may be investigated. However, the research 
community has established tremendous worth to de-
ciphering these systems. Finally, the advent of new 
sequencing and analysis technologies assure that 
these pathways will continue to be investigated until 
preventative cardiac medicine is a reality. 
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